Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 15/20 | 0.40 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957933 | 1.00 | KLKB1 (0.40) | KLKB1METTL3P2RX3P2RX2ALDH1A1 | |
| SCHEMBL27033856 | 0.90 | KLKB1 (0.35) | KLKB1METTL3P2RX3P2RX2ALDH1A1 | |
| SCHEMBL29958373 | 0.90 | KLKB1 (0.35) | KLKB1METTL3P2RX3P2RX2ALDH1A1 | |
| SCHEMBL29958064 | 0.85 | KLKB1 (0.37) | KLKB1METTL3LRRK2 | |
| SCHEMBL27033452 | 0.85 | KLKB1 (0.37) | KLKB1METTL3LRRK2 | |
| SCHEMBL27033821 | 0.84 | KLKB1 (0.42) | KLKB1METTL3 | |
| SCHEMBL29958170 | 0.84 | KLKB1 (0.42) | KLKB1METTL3 | |
| SCHEMBL29958167 | 0.84 | KLKB1 (0.40) | KLKB1METTL3 | |
| SCHEMBL24729704 | 0.82 | METTL3 (0.44) | KLKB1METTL3 | |
| Formic Acid SCHEMBL27033368 | 0.81 | KLKB1 (0.41) | KLKB1METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-21 | — | — | US | disclosed |
| EP-4308228-A1 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885METTL3 4613/4885P2RX3 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.